The non-syndromic clinical spectrums of mtDNA 3243A>G mutation

Xiya Shen, MD, Ailian Du, MD, PhD.

ABSTRACT

The m.3243A>G mutation in the tRNA Leu (UUR) gene (MT-TL1) is one of the most common pathogenic mtDNA mutations. The phenotypes of m.3243A>G mutation are in great variety in manifestations and severity, ranging from fatal to asymptomatic. The affected tissues or organs include the nervous system, skeletal muscles, heart muscles, ears, eyes, kidneys, liver and endocrine system. Some phenotypes conform to well established syndromes, while most of the symptoms appear individually or concomitant to other syndromes, making identification difficult. Furthermore, some progress has been made on cardiac manifestations as well as complications during pregnancy and perinatal period. This article provides a systematic review of the non-syndromic phenotypes and latest developments in m.3243A>G mutation.
Non-syndromic phenotype 3243A>G mutation ... Shen & Du

Neurological and mental impairment. Psychiatric disorders. Mental disorders including depression, personality disorders, schizophrenia, and panic disorders in m.3243A>G mutation patients were first reported in 1997, and have been rapidly increasing and becoming more specific in recent years. Verhaak et al. studied 122 patients carrying m.3243A>G mutation and found that 37% of them exhibited mental health problems, such as depression and anxiety, which was significantly more than healthy normal people. A study comprising 202 m.3243A>G mutation patients from Newcastle (UK) found that half of the patients had mild psychiatric symptoms such as reactive depression, while 19% had moderate to severe psychiatric symptoms. The Newcastle study also proposed a hypothesis that mental illness may be related to abnormal brain function because they found that 22 out of 202 patients had both encephalopathy and mental disorders, and 19 patients had evidence of encephalopathy before the onset of psychiatric symptoms. The heritability of psychiatric problems in m.3243A>G mutation patients is larger than that of major depression in the population, which is estimated to be 31-42%. Headache and migraine. Migraine is defined as recurrent, mostly unilateral, moderate to severe, and pulsatile headaches, with an annual incidence of about 12% in the general adult population. The prevalence of migraine happened in patients with m.3243A>G mutation varies from 29-58%, which is higher than that of the general population. Two recent research from Europe have focused on headaches in mitochondrial disease. Tiehuis et al. has reported 56 % headache out of 62 mitochondrial disease patients, of which 48% met the ICHD-3 Migraine-criteria. Report from the UK Newcastle group showed that 66.7% of patients had primary neuropathic chronic pain. The m.3243A>G MTTL1 mutation patients showed higher pain severity and higher possibility of neuropathic pain compared to other causative mtDNA and nuclear DNA mutations. Smeitink J et al. proposed that the disentangling of the angiopathy paradigm, ROS-redox metabolism, or ROS-induced inflammation pathways might be the mechanisms of mitochondrial migraine. In the study from The Newcastle Group, migraine related to m.3243A>G mutation showed a moderate correlation with gastrointestinal dysfunction (r=-0.45). Thus, they hypothesized that a similar biological mechanism underlying these two conditions may be involved in the genes of smooth muscle function.

Other neurological symptoms. Multiple peripheral neuropathy is very common in m.3243A>G mutation patients. The clinical manifestations range from subclinical peripheral nerve damage to severe peripheral neuropathy, which can be one of the multiple system damages or exist alone. Cerebellar ataxia appears in about 66% patients with m.3243A>G mutation, which indicated moderate to large possibility of heritability in-line with migraine, psychiatric involvement, and hearing impairment. Progressive cognitive regression, brain volume shrinkage, and extensive white matter lesions are also important features of syndromic and non-syndromic patients with m.3243A>G mutations.

Mitochondrial myopathy. The main manifestations of mitochondrial muscle involvement are exercise intolerance, muscle weakness, myalgia and muscle atrophy. Muscle weakness is a common symptom of various clinical syndromes such as MELAS, CPEO, KSS, MERRF, etc. Occasionally, it manifests as isolated myopathy. The majority of mitochondrial myopathies are chronic. However in some conditions, it can manifest as acute onset muscle pain, muscle weakness, palpitations, dyspnea, and lactate acidosis. This life-threatening condition can be trigged by strenuous exercise, fatigue, drinking, sedative drugs, etc. Zhou et al. reported three cases of severe mitochondrial myopathy, of which one case had cardiac arrest and died after the first attack, while two cases survived the metabolic crisis and remained in stable condition with long-term medication. Pan et al. reported five patients with respiratory failure and lactate acidosis caused by m.3243A>G mutation triggered by sedative drugs. Endocrine system involvement. The common endocrine system involvements in m.3243A>G mutation include the pancreas, thyroid, parathyroid, pituitary, and gonads. In an observational study of 35 patients carrying m.3243A>G mutation, the incidence of endocrine-related manifestations were as follows: 18 (51.4%) cases with diabetes, 8 (22.9%) cases of short stature, 8 (22.9%) cases with elevated lactate, 3 (8.6%) cases with elevated pyruvate and 2 (5.7%) cases with hypothyroidism. The most common disease of the endocrine system is mitochondrial diabetes, which accounts for 0.5-2.8% of diabetes mellitus. About 85% of mitochondrial-derived diabetes can be attributed to m.3243A>G mutations, which is often concomitant with low body mass index. Short

Disclosure. This work was supported by Shanghai Natural Science Foundation (19ZR1449200) and National Natural Science Foundation of China (81971181), the Medical and Engineering Crossover Fund of SJTU (YG2017MS67).
stature is another common feature in m.3243A>G mutation carriers, which may be partially related to growth hormone deficiency.⁷

**Cardiovascular involvement.** Cardiac manifestations in m.3243A>G mutation patients are common and serious. The presentations include hypertrophic or dilated cardiomyopathy, heart failure, conduction block, Wolff-Parkinson-White (WPW) syndrome,²⁹,³⁰ and ventricular or supraventricular tachycardia. Malfatti et al. analyzed cardiac abnormalities in 41 individuals carrying m.3243A>G mutation, of which 18 patients had left ventricular hypertrophy and dysfunction, while seven patients had WPW syndrome.⁵⁰ They indicated that left ventricular hypertrophy independently predicted adverse cardiac events.³⁰ Wahbi et al.³¹ studied predictors of severe adverse cardiac events in 260 mitochondrial disease patients, including 64 cases with m.3243A>G mutations. They found that patients with m.3243A>G point mutation or single large-scale deletions are mostly vulnerable to major cardiac adverse events. The main causes of death were heart failure and cardiac arrest. In recent years, sudden adult death syndrome (SADS) in asymptomatic patients has also been recognized as a clinical entity in m.3243A>G mutation.⁵ Thus, it is important to conduct regular cardiac arrhythmia surveillance and cardiac echo in m.3243A>G mutation carriers.

**Visual and hearing impairment.** The most common ophthalmological manifestation due to m.3243A>G mutation is pigmented retinopathy, which can cause symptoms such as vision loss, visual field defect, night blindness, etc.³² Cortical blindness is also common when mitochondrial encephalopathy involves the visual cortex or posterior visual pathway in MELAS syndrome.³²,³³ The ocular complications of mitochondrial diabetes are cataracts, macular degeneration, or optic atrophy.²⁸ This is different from type 1 and type 2 diabetes complications, which is primarily diabetic retinopathy.²⁹ A study found that approximately 86% of MIDD patients exhibited macular dystrophy and pigmented retinopathy.²⁷

Hearing impairment is one of the most common clinical features of mitochondrial disease, accounting for 62.8% of m.3243A>G mutation carriers.⁷ The Newcastle group studied 238 m.3243A>G mutation patients found that up to 81% of patients had hearing impairment.¹² Hearing impairment may present alone

---

**Table 1 - Clinical phenotypes due to m.3243A>G mutation in the tRNA⁹ gene (UUR).**

| Syndromic phenotypes | Non-syndromic symptoms |
|----------------------|------------------------|
| **Neurological disorders** | MELAS, LS, MELAS/LS, KSS, CPEO, MERRF, NARP, |
| **Muscle disorders** | CPEO, MERRF |
| **Cardiovascular disorders** | SADS, WPW syndrome, |
| **Endocrine disorders** | MIDD |
| **Ocular impairment** | NARP, CPEO |
| **Otolaryngologic impairment** | MIDD |
| **Digestive system** | IPO |
| **Kidney impairment** | none |
| **Pregnancy and delivery** | none |
| **Others** | none |

MELAS - mitochondrial encephalomyopathy, lactic acidosis, stroke-like attack; LS - Leigh syndrome; KSS - Keams-Sayre syndrome; CPEO - chronic progressive external ophthalmoplegia; NARP - neurogenic weakness, ataxia, and retinitis pigmentosa; MERRF - myoclonic epilepsy and ragged-red fiber disease; SADS - sudden adult death syndrome; WPW - Wolff-Parkinson-White syndrome; MIDD - Maternally Inherited Diabetes and Deafness; IPO - Intestinal pseudo-obstruction
or as a symptom of syndromic MIDD and MELAS syndrome. The types of hearing impairment are mainly sensorineural hearing loss. Peripheral vestibular functional impairment was also reported. Therefore, combining visual and hearing impairments can be a useful clinical indicator for MT-TL1 m.3243A>G mutation diagnosis.

Gastrointestinal involvement. Gastrointestinal symptoms include vomiting, diarrhea, constipation, and gastrointestinal discomfort. Most of them are considered non-specific symptoms of mitochondrial disease. Vomiting and headache often present as the first symptom in MELAS syndrome patients and are recurrent. In a study of the Newcastle group, 76% of patients with m.3243A>G mutations had gastrointestinal symptoms, with the frequency secondary to deafness. In a study of 190 MELAS patients in China, the incidence of vomiting was 65.58%. Intestinal pseudo-obstruction (IPO) is a severe but easily ignored symptom in mitochondrial disease. The IPO is a clinical syndrome, which includes long-term nausea, vomiting, abdominal pain, and significant abdominal distension associated with severe constipation, imaging shows intestinal loop dilation, with the absence of any lesion occluding the gut. The presentation of IPO is often an indicator of poor prognosis. In a study involving 226 patients with m.3243A>G mutations, 30 cases had IPO, of which 14 cases had concurrent IPO and MELAS syndrome. Rare cases such as IPO with diabetes and recurrent pancreatitis have also been reported.

Pregnancy and delivery. Women carrying mtDNA mutations are vulnerable to obstetric complications such as miscarriage, gestational diabetes, premature delivery, intrauterine growth retardation, and preeclampsia than normal women and nDNA mutation carriers. Feeney et al analyzed the complications of 67 pregnant women and found that pregnant women with m.3243A>G mutations had a higher risk of gestational diabetes, cesarean section and premature delivery than those with other types of mitochondrial diseases. Of the 67 live births, the premature birth rate was as high as 53.3%, and extremely premature babies (<32 weeks old) accounted for 12.9%. De Laat et al analyzed 46 pregnant women with m.3243A>G mutation, including 98 pregnancies. The obstetric complications were preterm birth (25.3%), preeclampsia (12%), and gestational diabetes (11%). These results suggested that pregnant women carrying m.3243A>G mutations have a very high risk of perinatal complications, miscarriage, and premature delivery, which require close monitoring for genetic counseling and maternal care.

Heteroplasmy and phenotype variety. The reason for phenotypes variety of m.3243A>G mutation is not fully clear to date. Heteroplasmy level (a state that wild-type and mutant mtDNA co-exist in the same cell at different ratio) contribute to the phenotype properties. Higher heteroplasmy level often present more severe clinical phenotypes such as seizure, MELAS, myopathy and related to younger onset age. While lower heteroplasmy level were more likely to suffer from hearing loss, decreased vision, and gastrointestinal disturbance. Phenotype is also modulated by nuclear gene and environmental factors. Recent report based 238 patients carrying 3243As>G mutation from New Castle found that nuclear factor may contribute larger than other known factors such as age, gender, and heteroplasmy.

Disease course and prognosis. The course and prognosis of mitochondrial disease due to m.3243A>G mutation are affected by many factors. Higher heteroplasmy level, nervous system involvement, presentation of IPO are closely related to poor prognosis. Recent 6 year follow up on 151 m.3243A>G mutation carriers showed that slowly progression of clinical score by 0.47 point increase of Newcastle Mitochondrial Disease Adult Scale (NMDAS) score per year. Sun et al. analyzed 64 patients with MELAS syndrome and found that the medium survival time was 12 years. The medium survival time of patients with onset before 14 years old was eight years, which was significantly shorter than those with onset after sexual maturity (21 years). In adults, the most common reason of death included sudden cardiac death, epilepticus status, stroke-like attacks, aspiration failure, paralytic intestinal obstruction, sepsis, and metabolic acidosis.

Conclusion. The phenotype of mtDNA m.3243A>G mutation is highly heterogeneous. It is crucial to identify key symptoms, such as repeated vomiting, early onset diabetes, deafness, family history of miscarriage and multi-system involvement, in order to facilitate an earlier diagnosis. Moreover, screening asymptomatic carriers is particularly important to prevent sudden death syndrome. Furthermore, high pregnancy complications in m.3243A>G mutation cases poses great challenges in obstetrics and gynecology, pediatrics, and genetic counseling.

Acknowledgements. The authors gratefully acknowledge MedSci for native English editing. The authors also thank Dr. Yu Xia, MD for literatures collection and format editing.

References

1. Finsterer J, Zarrouk-Mahjoub S. Assessment of the phenotype genotype variability and correlation in m.3243A>G mutation carriers requires prospective studies. Mol Genet Metab Rep 2016; 8: 33.
2. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. *Ann Neurol* 2015; 77: 753-759.

3. Ng YS, Grady JP, Lax NZ, Bourke JP, Alston CL, Hardy SA, et al. Sudden adult death syndrome in m.3243A>G-related mitochondrial disease: an unrecognized clinical entity in young, asymptomatic adults. *Eur Heart J* 2016; 37: 2552-2559.

4. Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic mitochondrial DNA mutations are common in the general population. *Am J Hum Genet* 2008; 83: 254-260.

5. de Laat P, Fleuren LH, Bekker MN, Smeitink JA, Janssen J. Mitochondrial Migraine: Disentangling the angiopathy paradigm in m.3243A>G patients. *JIMD Rep* 2019; 46: 52-62.

6. Dodick DW. Migraine. *The Lancet* 2018; 391: 1315-30.

7. Kraya T, Deschauer M, Joshi PR, Zierz S, Gaul C. Prevalence of Headache in Patients With Mitochondrial Disease: A Cross-Sectional Study. *Headache* 2018; 58: 45-52.

8. van den Ameele J, Fuge J, Pinceatly RDS, Berry S, McIntyre Z, Hanna MG, et al. Chronic pain is common in mitochondrial disease. *Neuromuscul Disord* 2020; 30: 413-419.

9. Smeitink J, Koene S, Beyrauth J, Saris C, Turnbull D, Janssen M. Mitochondrial Migraine: Disentangling the angiopathy paradigm in m.3243A>G patients. *JIMD Rep* 2019; 46: 52-62.

10. Kaufmann P, Pascual JM, Anziska Y, Gooch CL, Engelstad K, Jhung S, et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. *Arch Neurol* 2006; 63: 746-748.

11. Tsukijawa K, Senda J, Yasui K, Hasegawa Y, Hoshiyama M, Katsuno M, et al. Distinctive distribution of brain volume reductions in MELAS and mitochondrial DNA A3243G mutation carriers: A voxel-based morphometric study. *Mitochondrion* 2016; 30: 229-235.

12. Yokoyama T, Hasegawa K, Obama R, Ishihara T, Yagishita S. MELAS with diffuse degeneration of the cerebral white matter: report of an autopsy case. *Neuropathology* 2010; 30: 56-60.

13. Ma Y, Fang F, Cao Y, Yang Y, Zou L, Zhang Y, et al. Clinical features of mitochondrial DNA m.3243A>G mutation in 47 Chinese families. *J Neurol Sci* 2010; 291: 17-21.

14. Zhou Y, Yi J, Liu L, Wang X, Dong L, Du A. Acute mitochondrial myopathy with respiratory insufficiency and motor axonal polyneuropathy. *Int J Neurol Sci* 2018; 128: 231-236.
36. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015; 116: 4-12.
37. Zhang Z, Zhao D, Liu J, Zuo Y, Xiong H, Lyu H, et al. Clinical features of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes: an analysis of 190 cases. Chinese Journal of Neurology 2016; 49: 237-242.
38. Stanghellini V, Cogliandro RF, de Giorgio R, Barbara G, Sàv oldi B, Corinaldesi R. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil 2007; 19: 440-452.
39. Ng YS, Feeney C, Schaefer AM, Holmes CE, Hynd P, Alston CL, et al. Pseudo-obstruction, stroke, and mitochondrial dysfunction: A lethal combination. Ann Neurol 2016; 80: 686-692.
40. Verny C, Amati-Bonneau P, Letournel F, Person B, Dih N, Malinge MC, et al. Mitochondrial DNA A3243G mutation involved in familial diabetes, chronic intestinal pseudo-obstruction and recurrent pancreatitis. Diabetes Metab 2008; 34: 620-626.
41. Say RE, Whittaker RG, Turnbull HE, McFarland R, Taylor RW, Turnbull DM. Mitochondrial disease in pregnancy: a systematic review. Obstet Med 2011; 4: 90-94.
42. Kuleva M, Ben Miled S, Steffann J, Bonnefont JP, Rondeau S, Ville Y, et al. Increased incidence of obstetric complications in women carrying mitochondrial DNA mutations: a retrospective cohort study in a single tertiary centre. BJOG 2019; 126: 1372-1379.
43. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, et al. Protein phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol 2009; 66: 85-91.
44. Chae HW, Na JH, Kim HS, Lee YM. Mitochondrial diabetes and mitochondrial DNA mutation load in MELAS syndrome. Eur J Endocrinol 2020; 183: 505-512.
45. Xia CY, Liu Y, Liu H, Zhang YC, Ma YN, Qi Y. Clinical and Molecular Characteristics in 100 Chinese Pediatric Patients with m.3243A>G Mutation in Mitochondrial DNA. Chin Med J (Engl) 2016; 129: 1945-1949.
46. Liu G, Shen X, Sun Y, Lv Q, Li Y, Du A. Heteroplasmy and phenotype spectrum of the mitochondrial tRNA(Leu(UUR)) gene m.3243A>G mutation in seven Han Chinese families. J Neurosci Sci 2020; 408: 116562.
47. de Laat P, Rodenburg RR, Roeleveld N, Koene S, Smeitink JA, Janssen MC. Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A>G variant. J Med Genet 2020.
48. Sun C, Lin J, Cai S, Zhu W, Luo S, Xi J, et al. A clinical and natural history research on mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. Chinese Journal of Neurology 2018; 51: 118-123.
49. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, et al. Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. Neurology 2011; 77: 1965-1971.
50. Klopstock T, Jaksch M, Gasser T. Age and cause of death in mitochondrial diseases. Neurology 1999; 53: 855-857.

Copyright

Whenever a manuscript contains material (tables, figures, etc.) which is protected by copyright (previously published), it is the obligation of the author to obtain written permission from the holder of the copyright (usually the publisher) to reproduce the material in Saudi Medical Journal. This also applies if the material is the authors own work. Please submit copies of the material from the source in which it was first published.